EpCAM (epithelial cell adhesion molecule) was discovered four decades ago as a tumor
antigen on colorectal carcinomas. Owing to its frequent and high expression on carcinomas …

Antibody‐based cancer therapy, one of the most significant therapeutic strategies, has
achieved considerable success and progress over the past decades. Nevertheless …

In the last few decades, the epithelial cell adhesion molecule (EpCAM) has received
increased attention as the main membrane marker used in many enrichment technologies to …

Cancers are heterogeneous at the cell level, and the mechanisms leading to cancer
heterogeneity could be clonal evolution or cancer stem cells. Cancer stem cells are resistant …

Adoptive chimeric antigen receptor‐modified T or NK cells (CAR‐T or CAR‐NK) offer new
options for cancer treatment. CAR‐T therapy has achieved encouraging breakthroughs in …

Background Epithelial cell adhesion molecule (EpCAM) is known to highly expression and
promotes cancer progression in many cancer types, including colorectal cancer. While …

Although epithelial cell adhesion molecule (EpCAM) has previously been shown to promote
tumor progression, the underlying mechanisms remain largely unknown. Here, we report …

Colorectal cancer (CRC) is one of the most common malignancies worldwide. In spite of
various attempts to ameliorate outcome by escalating treatment, significant improvement is …

Epithelial cell adhesion molecule (EpCAM) is highly expressed in colon cancers, but its role
in cancer progression remains to be elucidated. In this work, we found that the extracellular …

The epithelial cell adhesion molecule (EpCAM) is a Type I transmembrane superficial
glycoprotein antigen that is expressed on the surface of basolateral membrane of multiple …